These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30488833)

  • 1. A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas.
    Bandlamudi BP; Sharan K; Yathiraj PH; Singh A; Reddy A; Fernandes DJ; Srinivasa VM
    J Cancer Res Ther; 2018; 14(6):1220-1224. PubMed ID: 30488833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xerostomia after radiotherapy. What matters--mean total dose or dose to each parotid gland?
    Tribius S; Sommer J; Prosch C; Bajrovic A; Muenscher A; Blessmann M; Kruell A; Petersen C; Todorovic M; Tennstedt P
    Strahlenther Onkol; 2013 Mar; 189(3):216-22. PubMed ID: 23354440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
    Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
    Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy or volumetric-modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry.
    Vallard A; Guy JB; Mengue Ndong S; Vial N; Rivoirard R; Auberdiac P; Méry B; Langrand-Escure J; Espenel S; Moncharmont C; Ben Mrad M; Diao P; Goyet D; Magné N
    Head Neck; 2016 Jul; 38(7):1028-34. PubMed ID: 26855006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.
    Lambrecht M; Nevens D; Nuyts S
    Strahlenther Onkol; 2013 Mar; 189(3):223-9. PubMed ID: 23319256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compensator-based intensity-modulated radiotherapy in head and neck cancer: our experience in achieving dosimetric parameters and their clinical correlation.
    Nangia S; Chufal KS; Arivazhagan V; Srinivas P; Tyagi A; Ghosh D
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):485-92. PubMed ID: 16909973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volume changes during head-and-neck radiotherapy and its impact on the parotid dose - A single-institution observational study.
    Ilangovan B; Venkatraman M; Balasundaram S
    J Cancer Res Ther; 2020; 16(3):575-580. PubMed ID: 32719270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model for predicting the dose to the parotid glands based on their relative overlapping with planning target volumes during helical radiotherapy.
    Millunchick CH; Zhen H; Redler G; Liao Y; Turian JV
    J Appl Clin Med Phys; 2018 Mar; 19(2):48-53. PubMed ID: 29105949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
    Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
    Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.